STRX-220

N/A

Report date: 2023/10/26 17:01:28

Base Information

Drug NameSTRX-220
Drug Alias NameSTRX-220
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionGene transferenceUbiquitin-like modifier-activating enzyme 3A stimulants
TargetsUbiquitin-like modifier-activating enzyme 3A
Therapy Area/IndicationsAngelman Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesStridebio Inc
China Registration ClassN/A

Develop Information

Active CompaniesSarepta Therapeutics IncStridebio Inc
Inactive CompaniesN/A
Active IndicationsAngelman Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A